A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

NCT01077544 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
15
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Novartis Pharmaceuticals